Piotr Roszczenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Piotr Roszczenko has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Olga Klaudia Szewczyk-Roszczenko
Department of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland
13 shared publications - Krzysztof Bielawski
Department of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland
12 shared publications - Anna Bielawska
Department of Biotechnology, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland
10 shared publications - Robert Czarnomysy
Department of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland
8 shared publications - Roman Lesyk
Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine
5 shared publications - Agnieszka Gornowicz
Department of Biotechnology, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland
4 shared publications
Latest Publications
- 22 August 2026
- Published by Elsevier in Fungal Biology Reviews
- Vol. 58
Genotoxic and genoprotective effects of fungi
- 22 August 2026
- Published by Elsevier in Fungal Biology Reviews
- Vol. 58
Genotoxic and genoprotective effects of fungi
- Open Access
Anticancer Properties of Selected Wood-Inhabiting Fungi
Wood-inhabiting fungi constitute a valuable source of biologically active compounds with significant therapeutic potential. Particular attention is paid to species known for their high content of polysaccharides, triterpenoids, phenolic compounds, and other secondary metabolites exhibiting cytotoxic and immunomodulatory activities. The results indicate that extracts obtained from these fungi may inhibit tumor growth, induce apoptosis, and support the immune response of the organism. Although further clinical studies are required, wood-inhabiting medicinal fungi represent a promising direction in the development of natural anticancer therapies and complementary treatment strategies.
Open AccessAnticancer Properties of Selected Wood-Inhabiting Fungi
Wood-inhabiting fungi constitute a valuable source of biologically active compounds with significant therapeutic potential. Particular attention is paid to species known for their high content of polysaccharides, triterpenoids, phenolic compounds, and other secondary metabolites exhibiting cytotoxic and immunomodulatory activities. The results indicate that extracts obtained from these fungi may inhibit tumor growth, induce apoptosis, and support the immune response of the organism. Although further clinical studies are required, wood-inhabiting medicinal fungi represent a promising direction in the development of natural anticancer therapies and complementary treatment strategies.
- Open Access
- 16 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (12) , 1510
Plant-Based Care and Therapy in Ophthalmology
Oxidative stress, inflammation, and environmental factors contribute significantly to the development of ocular disorders, including dry eye disease, conjunctivitis, and age-related degenerative changes. In recent years, growing attention has been directed toward natural compounds and plant-derived extracts with potential protective and therapeutic effects on eye health. This work provides an overview of selected bioactive substances, such as carotenoids (β-carotene), flavonoids, vitamins C and E, and phytochemicals derived from plants. These agents exhibit antioxidative, anti-inflammatory, antimicrobial, and regenerative properties that may support ocular surface integrity, reduce oxidative damage, and improve visual performance. The integration of such natural remedies into ocular health strategies may offer complementary benefits to conventional therapies.
- 16 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (12) , 1510
Open AccessPlant-Based Care and Therapy in Ophthalmology
Oxidative stress, inflammation, and environmental factors contribute significantly to the development of ocular disorders, including dry eye disease, conjunctivitis, and age-related degenerative changes. In recent years, growing attention has been directed toward natural compounds and plant-derived extracts with potential protective and therapeutic effects on eye health. This work provides an overview of selected bioactive substances, such as carotenoids (β-carotene), flavonoids, vitamins C and E, and phytochemicals derived from plants. These agents exhibit antioxidative, anti-inflammatory, antimicrobial, and regenerative properties that may support ocular surface integrity, reduce oxidative damage, and improve visual performance. The integration of such natural remedies into ocular health strategies may offer complementary benefits to conventional therapies.
- Open Access
- 4 December 2025
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 40 (1) , 2594158
Sulphonamide derivatives with a triazine core as novel inducers of apoptosis and pyroptosis in glioblastoma multiforme cells
Glioblastoma multiforme (GBM) is a highly aggressive brain tumour with few effective treatment options. This study evaluated two novel triazine-based sulphonamides, MM118 and MM119, for their anticancer effects on GBM cells. In vitro cell viability assays showed that both compounds were highly potent, killing GBM cells at low-micromolar concentrations. They induced apoptosis in cancer cells, evidenced by Annexin V/PI staining and caspase-3/7 activation. Both the intrinsic and extrinsic apoptosis pathways were engaged, as shown by mitochondrial depolarisation along with caspase-9 and caspase-8 activation. The compounds also increased reactive oxygen species levels, further promoting apoptosis. Notably, MM118 and MM119 triggered pyroptosis - an inflammatory form of cell death - indicated by caspase-1 activation and NF-κB translocation. In a zebrafish xenograft model, both compounds significantly reduced tumour growth. These findings highlight MM118 and MM119 as promising candidates for GBM therapy that may overcome resistance by engaging multiple cell-death pathways.
- 4 December 2025
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 40 (1) , 2594158
Open AccessSulphonamide derivatives with a triazine core as novel inducers of apoptosis and pyroptosis in glioblastoma multiforme cells
Glioblastoma multiforme (GBM) is a highly aggressive brain tumour with few effective treatment options. This study evaluated two novel triazine-based sulphonamides, MM118 and MM119, for their anticancer effects on GBM cells. In vitro cell viability assays showed that both compounds were highly potent, killing GBM cells at low-micromolar concentrations. They induced apoptosis in cancer cells, evidenced by Annexin V/PI staining and caspase-3/7 activation. Both the intrinsic and extrinsic apoptosis pathways were engaged, as shown by mitochondrial depolarisation along with caspase-9 and caspase-8 activation. The compounds also increased reactive oxygen species levels, further promoting apoptosis. Notably, MM118 and MM119 triggered pyroptosis - an inflammatory form of cell death - indicated by caspase-1 activation and NF-κB translocation. In a zebrafish xenograft model, both compounds significantly reduced tumour growth. These findings highlight MM118 and MM119 as promising candidates for GBM therapy that may overcome resistance by engaging multiple cell-death pathways.
- Open Access
- 22 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 23267-23276
Apoptosis, Oxidative Stress, and Cell Cycle Disruption: Antitumor Effects of a Novel Palladium(II) Complexes
The development of novel metal-based anticancer agents with higher selectivity and lower toxicity is a major goal in oncology. In this study, four newly synthesized palladium(II) complexes (1a, 1b, 1c, 2a) were tested for cytotoxicity against breast cancer cell lines MCF-7 and MDA-MB-231, with cisplatin as reference. Complexes 1a, 1b, and 2a showed strong activity, particularly in MCF-7. Flow cytometry revealed that complex 2a induced S-phase arrest in MCF-7 and G2/M arrest in MDA-MB-231. ROS detection assays confirmed a marked increase in oxidative stress after 2a treatment, accompanied by mitochondrial membrane potential loss. Furthermore, caspase-9 and caspase-8 activation, along with downstream caspases 3 and 7, indicated engagement of both intrinsic and extrinsic apoptotic pathways. Among the tested compounds, palladium complex 2a exhibited the most potent and multifaceted anticancer activity. These results highlight 2a as a promising candidate scaffold for further development of novel chemotherapeutics targeting breast cancer.
- 22 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 23267-23276
Open AccessApoptosis, Oxidative Stress, and Cell Cycle Disruption: Antitumor Effects of a Novel Palladium(II) Complexes
The development of novel metal-based anticancer agents with higher selectivity and lower toxicity is a major goal in oncology. In this study, four newly synthesized palladium(II) complexes (1a, 1b, 1c, 2a) were tested for cytotoxicity against breast cancer cell lines MCF-7 and MDA-MB-231, with cisplatin as reference. Complexes 1a, 1b, and 2a showed strong activity, particularly in MCF-7. Flow cytometry revealed that complex 2a induced S-phase arrest in MCF-7 and G2/M arrest in MDA-MB-231. ROS detection assays confirmed a marked increase in oxidative stress after 2a treatment, accompanied by mitochondrial membrane potential loss. Furthermore, caspase-9 and caspase-8 activation, along with downstream caspases 3 and 7, indicated engagement of both intrinsic and extrinsic apoptotic pathways. Among the tested compounds, palladium complex 2a exhibited the most potent and multifaceted anticancer activity. These results highlight 2a as a promising candidate scaffold for further development of novel chemotherapeutics targeting breast cancer.
- Open Access
Trastuzumab Potentiates Antitumor Activity of Thiopyrano[2,3-d]Thiazole Derivative in AGS Gastric Cancer Cells
Gastric cancer remains a significant therapeutic challenge, highlighting the need for new strategies to improve treatment efficacy. This study investigates the potential of combined therapy with the novel Thiopyrano[2,3-d]Thiazole derivative LES-6400 and the anti-HER2 antibody trastuzumab in AGS gastric cancer cells. The antitumor effects of the combined therapy were evaluated using various techniques, including the MTT assay for cell viability, [3H]-thymidine incorporation for DNA synthesis, and flow cytometry to assess apoptosis (Annexin V-FITC/PI staining), mitochondrial membrane potential (MMP), and inflammatory cytokine levels. ELISA was employed to measure the levels of IL-6, p53, and cytochrome C. The combination of LES-6400 (1 µM) and trastuzumab (10 µg/mL) demonstrated superior antitumor activity compared to monotherapy with either agent in AGS gastric cancer cells. The combination therapy enhanced apoptosis, presumably by inducing oxidative stress in the cells and disrupting mitochondrial membrane potential. Additionally, a significant increase in p53 protein levels and modulation of interleukin levels, including a marked reduction in IL-6 levels, were observed, suggesting an impact on apoptotic and inflammatory responses. These findings indicate that the combined use of LES-6400 and trastuzumab is a promising therapeutic strategy for gastric cancer, warranting further investigation into the mechanisms of action and potential clinical applications of this combined approach.
Open AccessTrastuzumab Potentiates Antitumor Activity of Thiopyrano[2,3-d]Thiazole Derivative in AGS Gastric Cancer Cells
Gastric cancer remains a significant therapeutic challenge, highlighting the need for new strategies to improve treatment efficacy. This study investigates the potential of combined therapy with the novel Thiopyrano[2,3-d]Thiazole derivative LES-6400 and the anti-HER2 antibody trastuzumab in AGS gastric cancer cells. The antitumor effects of the combined therapy were evaluated using various techniques, including the MTT assay for cell viability, [3H]-thymidine incorporation for DNA synthesis, and flow cytometry to assess apoptosis (Annexin V-FITC/PI staining), mitochondrial membrane potential (MMP), and inflammatory cytokine levels. ELISA was employed to measure the levels of IL-6, p53, and cytochrome C. The combination of LES-6400 (1 µM) and trastuzumab (10 µg/mL) demonstrated superior antitumor activity compared to monotherapy with either agent in AGS gastric cancer cells. The combination therapy enhanced apoptosis, presumably by inducing oxidative stress in the cells and disrupting mitochondrial membrane potential. Additionally, a significant increase in p53 protein levels and modulation of interleukin levels, including a marked reduction in IL-6 levels, were observed, suggesting an impact on apoptotic and inflammatory responses. These findings indicate that the combined use of LES-6400 and trastuzumab is a promising therapeutic strategy for gastric cancer, warranting further investigation into the mechanisms of action and potential clinical applications of this combined approach.
- Open Access
The Anticancer Potential of Edible Mushrooms: A Review of Selected Species from Roztocze, Poland
Edible mushrooms are not only a valued culinary ingredient but also have several potential medicinal and industrial applications. They are a rich source of protein, fiber, vitamins, minerals, and bioactive compounds such as polysaccharides and terpenoids, and thus have the capacity to support human health. Some species have been shown to have antioxidant, anti-inflammatory, anticancer, and immunomodulatory properties. We have therefore attempted to summarize the potential properties of the edible mushrooms popular in Poland, in the Roztocze area.
Open AccessThe Anticancer Potential of Edible Mushrooms: A Review of Selected Species from Roztocze, Poland
Edible mushrooms are not only a valued culinary ingredient but also have several potential medicinal and industrial applications. They are a rich source of protein, fiber, vitamins, minerals, and bioactive compounds such as polysaccharides and terpenoids, and thus have the capacity to support human health. Some species have been shown to have antioxidant, anti-inflammatory, anticancer, and immunomodulatory properties. We have therefore attempted to summarize the potential properties of the edible mushrooms popular in Poland, in the Roztocze area.
- Open Access
- 22 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (7) , 3571
Genetic Update and Treatment for Dystonia
A neurological condition called dystonia results in abnormal, uncontrollable postures or movements because of sporadic or continuous muscular spasms. Several varieties of dystonia can impact people of all ages, leading to severe impairment and a decreased standard of living. The discovery of genes causing variations of single or mixed dystonia has improved our understanding of the disease’s etiology. Genetic dystonias are linked to several genes, including pathogenic variations of VPS16, TOR1A, THAP1, GNAL, and ANO3. Diagnosis of dystonia is primarily based on clinical symptoms, which can be challenging due to overlapping symptoms with other neurological conditions, such as Parkinson’s disease. This review aims to summarize recent advances in the genetic origins and management of focal dystonia.
- 22 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (7) , 3571
Open AccessGenetic Update and Treatment for Dystonia
A neurological condition called dystonia results in abnormal, uncontrollable postures or movements because of sporadic or continuous muscular spasms. Several varieties of dystonia can impact people of all ages, leading to severe impairment and a decreased standard of living. The discovery of genes causing variations of single or mixed dystonia has improved our understanding of the disease’s etiology. Genetic dystonias are linked to several genes, including pathogenic variations of VPS16, TOR1A, THAP1, GNAL, and ANO3. Diagnosis of dystonia is primarily based on clinical symptoms, which can be challenging due to overlapping symptoms with other neurological conditions, such as Parkinson’s disease. This review aims to summarize recent advances in the genetic origins and management of focal dystonia.
- Open Access
- 29 January 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (2) , e29423
Chronic HIV‐1 Tat action induces HLA‐DR downregulation in B cells: A mechanism for lymphoma immune escape in people living with HIV
Despite the success of combination antiretroviral therapy, people living with human immunodeficiency virus (HIV) still have an increased risk of Epstein−Barr virus (EBV)‐associated B cell malignancies. In the HIV setting, B cell physiology is altered by coexistence with HIV‐infected cells and the chronic action of secreted viral proteins, for example, HIV‐1 Tat that, once released, efficiently penetrates noninfected cells. We modeled the chronic action of HIV‐1 Tat on B cells by ectopically expressing Tat or TatC22G mutant in two lymphoblastoid B cell lines. The RNA‐sequencing analysis revealed that Tat deregulated the expression of hundreds of genes in B cells, including the downregulation of a subset of major histocompatibility complex (MHC) class II‐related genes. Tat‐induced downregulation of HLA‐DRB1 and HLA‐DRB5 genes led to a decrease in HLA‐DR surface expression; this effect was reproduced by coculturing B cells with Tat‐expressing T cells. Chronic Tat presence decreased the NF‐ᴋB pathway activity in B cells; this downregulated NF‐ᴋB‐dependent transcriptional targets, including MHC class II genes. Notably, HLA‐DRB1 and surface HLA‐DR expression was also decreased in B cells from people with HIV. Tat‐induced HLA‐DR downregulation in B cells impaired EBV‐specific CD4+ T cell response, which contributed to the escape from immune surveillance and could eventually promote B cell lymphomagenesis in people with HIV.
- 29 January 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (2) , e29423
Open AccessChronic HIV‐1 Tat action induces HLA‐DR downregulation in B cells: A mechanism for lymphoma immune escape in people living with HIV
Despite the success of combination antiretroviral therapy, people living with human immunodeficiency virus (HIV) still have an increased risk of Epstein−Barr virus (EBV)‐associated B cell malignancies. In the HIV setting, B cell physiology is altered by coexistence with HIV‐infected cells and the chronic action of secreted viral proteins, for example, HIV‐1 Tat that, once released, efficiently penetrates noninfected cells. We modeled the chronic action of HIV‐1 Tat on B cells by ectopically expressing Tat or TatC22G mutant in two lymphoblastoid B cell lines. The RNA‐sequencing analysis revealed that Tat deregulated the expression of hundreds of genes in B cells, including the downregulation of a subset of major histocompatibility complex (MHC) class II‐related genes. Tat‐induced downregulation of HLA‐DRB1 and HLA‐DRB5 genes led to a decrease in HLA‐DR surface expression; this effect was reproduced by coculturing B cells with Tat‐expressing T cells. Chronic Tat presence decreased the NF‐ᴋB pathway activity in B cells; this downregulated NF‐ᴋB‐dependent transcriptional targets, including MHC class II genes. Notably, HLA‐DRB1 and surface HLA‐DR expression was also decreased in B cells from people with HIV. Tat‐induced HLA‐DR downregulation in B cells impaired EBV‐specific CD4+ T cell response, which contributed to the escape from immune surveillance and could eventually promote B cell lymphomagenesis in people with HIV.
- Open Access
- 23 January 2024
- Published by MDPI AG in Preprints.org
Focal Dystonia – an Update of Genetic Background and Novel Treatment
Dystonia is a neurological disorder that results in atypical uncontrolled motions or postures caused by either continuous or intermittent contractions of the muscles. Subtypes of dystonia vary in their symptoms and severity; they can affect people of all ages and cause significant disability and poor quality of life. Identifying genes responsible for single or mixed dystonia variants has improved our understanding of its pathogenesis. The mechanisms underlying several of the most prevalent genetic dystonias, including idiopathic dystonia, TOR1A, THAP1, and KMT2B mutations, involve anomalies in transcriptional regulation, striatal dopaminergic signaling, synaptic plasticity, and a loss of inhibition at neuronal circuits. Dystonia is mostly diagnosed based on clinical indicators, and the diagnosis and etiology of this illness remain a problem. In this review, we tried to summarize novel updates about genetic causes and treatment of focal dystonia.
- 23 January 2024
- Published by MDPI AG in Preprints.org
Open AccessFocal Dystonia – an Update of Genetic Background and Novel Treatment
Dystonia is a neurological disorder that results in atypical uncontrolled motions or postures caused by either continuous or intermittent contractions of the muscles. Subtypes of dystonia vary in their symptoms and severity; they can affect people of all ages and cause significant disability and poor quality of life. Identifying genes responsible for single or mixed dystonia variants has improved our understanding of its pathogenesis. The mechanisms underlying several of the most prevalent genetic dystonias, including idiopathic dystonia, TOR1A, THAP1, and KMT2B mutations, involve anomalies in transcriptional regulation, striatal dopaminergic signaling, synaptic plasticity, and a loss of inhibition at neuronal circuits. Dystonia is mostly diagnosed based on clinical indicators, and the diagnosis and etiology of this illness remain a problem. In this review, we tried to summarize novel updates about genetic causes and treatment of focal dystonia.